Related references
Note: Only part of the references are listed.The role of Shp2 (PTPN11) in cancer
M. Golam Mohi et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2
Elke Heiss et al.
BLOOD (2006)
Protein-tyrosine phosphatases and cancer
A Östman et al.
NATURE REVIEWS CANCER (2006)
Signal transduction of oncogenic Flt3
C Choudhary et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model
R Grundler et al.
BLOOD (2005)
Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases
DE Schmidt-Arras et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Flt3 receptor tyrosine kinase as a drug target in leukemia
D Schmidt-Arras et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
Regulation of interleukin-3-induced substrate phosphorylation and cell survival by SHP-2 (Src-homology protein tyrosine phosphatase 2)
H Wheadon et al.
BIOCHEMICAL JOURNAL (2003)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)